URSA-QUALITY-ADD2: ADD-E Continuation and Maintenance Phase (ADD2)

Measure Description

The percentage of members 6–12 years of age with a prescription dispensed for ADHD medication, who remained on the medication for at least 210 days and who, in addition to the visit in the initiation phase, had at least two follow-up visits with a practitioner within 270 days (9 months) after the initiation phase ended. Unadjusted Certified Measure 8d315e71-a472-4e0c-b8ef-4e117932d51b

Metadata

• Measure Type: Rate Measure
• Temporal Structure: Entity
• Component Class: Long-Form
• Denominator Case Field: Index Patient ID, Output NCQA Payer Type Code
• Target Direction: None

Denominator Description

Patients aged 6-12 years old who were dispensed an ADHD medication during the 12-month intake period.

Numerator Description

Qualifying denominator patients who had a follow-up visit with a practitioner with prescribing authority within 30 days following the index prescription start date and at least two (2) follow-up visits with a practitioner with prescribing authority from 31 to 300 days following the index prescription start date.

HEDIS® is a registered trademark of the National Committee for Quality Assurance (NCQA).